Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Share:
Related NBIX
Benzinga's Top Initiations
Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting
Neurocrine Bio files NDA for valbenazine for the treatment of tardive dyskinesia (Seeking Alpha)

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

DateFirmActionFromTo
Jun 2016H.C. WainwrightInitiates Coverage onBuy
Apr 2016BMO CapitalInitiates Coverage onOutperform
Feb 2016JP MorganMaintainsOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!